Agreed it will work well to great, given the fact

Agreed it will work well to great, given the fact that dosing will now be three times a week instead of once. If they had therapeutic benefit in patients that were merely exposed to K for one dose every week, just imagine what kind of response they are going to get by keeping K in the body three times longer! I am betting it is going to be jaw dropping. I also will make the prediction that this trial is going to demonstrate that K will likely need even further phase 2 trials where frequency of dosing is tested again. The phase 1 trial gave the first hints and the phase 2a trial will expand upon the effect of dose frequency, but they will want/need further data to find if additional therapeutic benefit is achievable with even more frequency. It will be awesome if those additional trials will be on other cancer lines to further demonstrate the broad spectrum of K, but they may have to stick with one type in order to ensure that they keep a proper baseline for comparison. Hopefully the completion of the K-OC trial will lead to the partnership we want and then the funding will be available for multiple concurrent K trials so that CTIX can quickly build an extremely robust profile on how powerful their drug really is.